Novolog Pharm (Israel) Buy Hold or Sell Recommendation
| NVLG Stock | 169.90 0.50 0.30% |
Assuming the 90 days trading horizon and complete risk avoidance on your part, our recommendation regarding Novolog Pharm Up 1966 is 'Strong Sell'. Macroaxis provides Novolog Pharm buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NVLG positions.
Check out Novolog Pharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Novolog and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Novolog Pharm Up 1966. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Novolog |
Execute Novolog Pharm Buy or Sell Advice
The Novolog recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novolog Pharm Up 1966. Macroaxis does not own or have any residual interests in Novolog Pharm Up 1966 or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novolog Pharm's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Novolog Pharm Trading Alerts and Improvement Suggestions
| Novolog Pharm Up 1966 has accumulated 916 K in total debt with debt to equity ratio (D/E) of 0.6, which is about average as compared to similar companies. Novolog Pharm Up has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novolog Pharm until it has trouble settling it off, either with new capital or with free cash flow. So, Novolog Pharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novolog Pharm Up sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novolog to invest in growth at high rates of return. When we think about Novolog Pharm's use of debt, we should always consider it together with cash and equity. | |
| About 42.0% of Novolog Pharm outstanding shares are owned by corporate insiders |
Novolog Pharm Returns Distribution Density
The distribution of Novolog Pharm's historical returns is an attempt to chart the uncertainty of Novolog Pharm's future price movements. The chart of the probability distribution of Novolog Pharm daily returns describes the distribution of returns around its average expected value. We use Novolog Pharm Up 1966 price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novolog Pharm returns is essential to provide solid investment advice for Novolog Pharm.
| Mean Return | 0.36 | Value At Risk | -2.2 | Potential Upside | 4.31 | Standard Deviation | 1.99 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novolog Pharm historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novolog Pharm Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novolog Pharm or Health Care Providers & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novolog Pharm's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novolog stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.36 | |
β | Beta against Dow Jones | -0.0082 | |
σ | Overall volatility | 1.67 | |
Ir | Information ratio | 0.12 |
Novolog Pharm Volatility Alert
Novolog Pharm Up 1966 has relatively low volatility with skewness of 1.2 and kurtosis of 2.95. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novolog Pharm's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novolog Pharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novolog Pharm Fundamentals Vs Peers
Comparing Novolog Pharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novolog Pharm's direct or indirect competition across all of the common fundamentals between Novolog Pharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novolog Pharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Novolog Pharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing Novolog Pharm by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novolog Pharm to competition |
| Fundamentals | Novolog Pharm | Peer Average |
| Return On Equity | 0.11 | -0.31 |
| Return On Asset | 0.0174 | -0.14 |
| Profit Margin | 0.03 % | (1.27) % |
| Operating Margin | 0.05 % | (5.51) % |
| Current Valuation | 1.45 B | 16.62 B |
| Shares Outstanding | 508.7 M | 571.82 M |
| Shares Owned By Insiders | 42.45 % | 10.09 % |
| Shares Owned By Institutions | 40.71 % | 39.21 % |
| Price To Book | 3.24 X | 9.51 X |
| Price To Sales | 0.99 X | 11.42 X |
| Revenue | 1.26 B | 9.43 B |
| Gross Profit | 154.67 M | 27.38 B |
| EBITDA | 115.92 M | 3.9 B |
| Net Income | 42.32 M | 570.98 M |
| Cash And Equivalents | 107.97 M | 2.7 B |
| Cash Per Share | 0.31 X | 5.01 X |
| Total Debt | 916 K | 5.32 B |
| Debt To Equity | 0.60 % | 48.70 % |
| Current Ratio | 0.96 X | 2.16 X |
| Book Value Per Share | 0.86 X | 1.93 K |
| Cash Flow From Operations | 83.39 M | 971.22 M |
| Earnings Per Share | 0.08 X | 3.12 X |
| Target Price | 2.1 | |
| Number Of Employees | 900 | 18.84 K |
| Beta | 0.2 | -0.15 |
| Market Capitalization | 1.09 B | 19.03 B |
| Total Asset | 2.29 B | 29.47 B |
| Annual Yield | 0.03 % | |
| Net Asset | 2.29 B | |
| Last Dividend Paid | 0.063 |
Novolog Pharm Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novolog . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 8828.92 | |||
| Daily Balance Of Power | 0.1316 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 169.9 | |||
| Day Typical Price | 169.9 | |||
| Price Action Indicator | 0.25 | |||
| Period Momentum Indicator | 0.5 |
About Novolog Pharm Buy or Sell Advice
When is the right time to buy or sell Novolog Pharm Up 1966? Buying financial instruments such as Novolog Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Novolog Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ISP Thematic Idea Now
ISP
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Novolog Stock
Novolog Pharm financial ratios help investors to determine whether Novolog Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novolog with respect to the benefits of owning Novolog Pharm security.